Lilia Zakhama
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Lilia Zakhama has a total of 384 co-authors. Here are the top co-authors by number of shared publications:
- Abraham Haileamlak
Editor-in-Chief, Ethiopian Journal of Health Sciences
21 shared publications - Chris Zielinski
University of Winchester, Winchester, UK
21 shared publications - David Ofori-Adjei
Editor-in-Chief, Ghana Medical Journal
21 shared publications - Fhumulani Mavis Mulaudzi
University of Pretoria
21 shared publications - Gregory E. Erhabor
West African Journal of Medicine, Lagos, Nigeria
21 shared publications - James Kashugyera Tumwine
School of Medicine, Kabale University, Kampala, Uganda
21 shared publications
Latest Publications
- 15 September 2026
- Published by Elsevier in Respiratory Medicine
- Vol. 263
Sleep apnea in stable heart failure: Clinical, polygraphic and echocardiographic characteristics
- 15 September 2026
- Published by Elsevier in Respiratory Medicine
- Vol. 263
Sleep apnea in stable heart failure: Clinical, polygraphic and echocardiographic characteristics
- Open Access
- 30 July 2026
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 15, e72944
Design of the Middle East African Registry for Women’s Cardiovascular Diseases: Protocol for a Multicenter Observational Study
Background: Cardiovascular disease (CVD) is a leading cause of morbidity and mortality in the Middle East and Africa (MEA), with a rising incidence particularly among women. Regional factors such as limited health care access, cultural barriers, and sex-specific risk factors exacerbate this burden. Despite this, women remain significantly underrepresented in cardiovascular research, and no large-scale, multicenter prospective trials have been conducted to provide national data. To address this gap, we established the Middle East African Registry Women Cardiovascular Disease (MEA-WCVD) to create a comprehensive database on the epidemiological profile and management of heart failure (HF), atrial fibrillation (AF), ischemic heart disease (IHD), and valvular heart disease (VHD) in women. Objective: The primary aim of this study is to compare the management of CVDs in women and men across MEA countries in accordance with current clinical practice guidelines. The study also seeks to identify gender-based disparities in health care insurance, income, and access to cardiovascular services. Methods: The MEA-WCVD is a prospective, multicenter, observational study enrolling consecutive patients aged ≥18 years with diagnosed HF, AF, IHD, or VHD across 25 tertiary care centers. Participants provide informed consent during a single visit, and trained investigators collect sociodemographic, clinical, and treatment data via electronic case report forms. The electronic case report form captures general characteristics (age, gender, and comorbidities) and diagnosis-specific details (imaging, guideline-based therapies, and complications). Data are stored in a centralized, contract research organization–managed database (Eshmoun-Clinical Research, Tunisia). An initial 75-day enrollment phase (May 2023-July 2023) is followed by a planned 1-year follow-up for outcome analysis. Data will be analyzed using SPSS (version 25) to compare gender disparities in management and outcomes using multivariable regression and survival analyses. Results: The MEA-WCVD study was funded in April 2023, and data collection began in May 2023. As of July 2023, a total of 15,366 participants have been enrolled across 25 centers. A 1-year follow-up is expected to be completed by July 2024. Data analysis is planned to commence in July 2024, with primary results anticipated for publication in March 2025. The study aims to establish the largest registry in the MEA region for HF, AF, IHD, and VHD, providing valuable insights into demographic trends, clinical management, and adherence to current guidelines. Conclusions: The MEA-WCVD registry will provide essential real-world data on the management and outcomes of the most prevalent CVDs (HF, AF, IHD, and VHD) in the MEA region. By directly comparing standard care management between men and women, this study will highlight gender disparities and inform future strategies for equitable cardiovascular care. The registry is expected to contribute to the largest contemporary cohort of patients with CVD in the region, advancing knowledge in cardiovascular epidemiology and clinical practice.
- 30 July 2026
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 15, e72944
Open AccessDesign of the Middle East African Registry for Women’s Cardiovascular Diseases: Protocol for a Multicenter Observational Study
Background: Cardiovascular disease (CVD) is a leading cause of morbidity and mortality in the Middle East and Africa (MEA), with a rising incidence particularly among women. Regional factors such as limited health care access, cultural barriers, and sex-specific risk factors exacerbate this burden. Despite this, women remain significantly underrepresented in cardiovascular research, and no large-scale, multicenter prospective trials have been conducted to provide national data. To address this gap, we established the Middle East African Registry Women Cardiovascular Disease (MEA-WCVD) to create a comprehensive database on the epidemiological profile and management of heart failure (HF), atrial fibrillation (AF), ischemic heart disease (IHD), and valvular heart disease (VHD) in women. Objective: The primary aim of this study is to compare the management of CVDs in women and men across MEA countries in accordance with current clinical practice guidelines. The study also seeks to identify gender-based disparities in health care insurance, income, and access to cardiovascular services. Methods: The MEA-WCVD is a prospective, multicenter, observational study enrolling consecutive patients aged ≥18 years with diagnosed HF, AF, IHD, or VHD across 25 tertiary care centers. Participants provide informed consent during a single visit, and trained investigators collect sociodemographic, clinical, and treatment data via electronic case report forms. The electronic case report form captures general characteristics (age, gender, and comorbidities) and diagnosis-specific details (imaging, guideline-based therapies, and complications). Data are stored in a centralized, contract research organization–managed database (Eshmoun-Clinical Research, Tunisia). An initial 75-day enrollment phase (May 2023-July 2023) is followed by a planned 1-year follow-up for outcome analysis. Data will be analyzed using SPSS (version 25) to compare gender disparities in management and outcomes using multivariable regression and survival analyses. Results: The MEA-WCVD study was funded in April 2023, and data collection began in May 2023. As of July 2023, a total of 15,366 participants have been enrolled across 25 centers. A 1-year follow-up is expected to be completed by July 2024. Data analysis is planned to commence in July 2024, with primary results anticipated for publication in March 2025. The study aims to establish the largest registry in the MEA region for HF, AF, IHD, and VHD, providing valuable insights into demographic trends, clinical management, and adherence to current guidelines. Conclusions: The MEA-WCVD registry will provide essential real-world data on the management and outcomes of the most prevalent CVDs (HF, AF, IHD, and VHD) in the MEA region. By directly comparing standard care management between men and women, this study will highlight gender disparities and inform future strategies for equitable cardiovascular care. The registry is expected to contribute to the largest contemporary cohort of patients with CVD in the region, advancing knowledge in cardiovascular epidemiology and clinical practice.
- Open Access
- 24 May 2026
- Published by Tunisian Society of Medical Sciences in La Tunisie medicale
- Vol. 104 (05)
Advancing clinical exercise physiology and integrative health policy in Tunisia: An international perspective on curriculum reform and professional recognition
Sedentary and non-communicable diseases continue to rise in Tunisia. Yet, graduates from the country’s four institutes of Sport Sciences face persistent barriers to employment and lack legal recognition within the healthcare system. Although these graduates receive academic learning and training in exercise physiology, biomechanics, adapted physical activity, and performance sciences, current legislation prevents them fromprescribing exercise or working with clinical populations. Across worldwide, many countries such as the United States, United Kingdom, Australia, and Canada have established regulated pathways for Clinical Exercise Physiologists, supported by accredited university programs, national certification systems, and clear scopes of practice. Global initiatives such as Exercise is Medicine®, active in many countries, further demonstratethe integration of physical activity into healthcare; however, Tunisia, like most Middle East and North Africa countries, remains unrepresented. In this policy-oriented narrative review, we reviewed the international models and propose a strategic roadmap for Tunisia to modernize sport-sciencecurricula, develop interdisciplinary degrees in exercise physiology, establish national accreditation and professional registration systems, authorize clinical practice, and integrate exercise into national health policy. Such reforms could reduce unemployment, enhance preventive healthcare, and align Tunisia with global standards in exercise-based medicine.
- 24 May 2026
- Published by Tunisian Society of Medical Sciences in La Tunisie medicale
- Vol. 104 (05)
Open AccessAdvancing clinical exercise physiology and integrative health policy in Tunisia: An international perspective on curriculum reform and professional recognition
Sedentary and non-communicable diseases continue to rise in Tunisia. Yet, graduates from the country’s four institutes of Sport Sciences face persistent barriers to employment and lack legal recognition within the healthcare system. Although these graduates receive academic learning and training in exercise physiology, biomechanics, adapted physical activity, and performance sciences, current legislation prevents them fromprescribing exercise or working with clinical populations. Across worldwide, many countries such as the United States, United Kingdom, Australia, and Canada have established regulated pathways for Clinical Exercise Physiologists, supported by accredited university programs, national certification systems, and clear scopes of practice. Global initiatives such as Exercise is Medicine®, active in many countries, further demonstratethe integration of physical activity into healthcare; however, Tunisia, like most Middle East and North Africa countries, remains unrepresented. In this policy-oriented narrative review, we reviewed the international models and propose a strategic roadmap for Tunisia to modernize sport-sciencecurricula, develop interdisciplinary degrees in exercise physiology, establish national accreditation and professional registration systems, authorize clinical practice, and integrate exercise into national health policy. Such reforms could reduce unemployment, enhance preventive healthcare, and align Tunisia with global standards in exercise-based medicine.
- Open Access
- 27 December 2025
- Published by Tunisian Society of Medical Sciences in La Tunisie medicale
- Vol. 103 (10) , 1350-1353
Training and Clinical Research Capacity Building in Low- and Middle-Income Countries: Addressing Unmet Needs
. The Middle East, Mediterranean, and Africa (MEMA) region, encompassing 68 countries and 20% of the global population, contributes only 6% of the world's registered clinical trials. This editorial identifies eight key barriers to clinical research in the region: (1) limited collaboration with high-income country (HIC) universities supporting low-income country (LIC) research, (2) insufficient specialized training programs, (3) inadequate laboratory and technological infrastructure, (4) lack of research methodology integration in medical curricula, (5) underdeveloped local institutional review boards, (6) insufficient and unsustainable funding, (7) limited technology transfer from HICs to LICs, and (8) migration of skilled professionals to HICs. These challenges hinder the region's research capacity and global contribution. Proposed solutions include fostering HIC-LMIC partnerships, enhancing training through scholarships and local research centers, improving infrastructure via international collaboration, and developing robust ethical review systems. By addressing these barriers, LMICs can increase their contribution to global clinical research, promoting equitable health outcomes.
- 27 December 2025
- Published by Tunisian Society of Medical Sciences in La Tunisie medicale
- Vol. 103 (10) , 1350-1353
Open AccessTraining and Clinical Research Capacity Building in Low- and Middle-Income Countries: Addressing Unmet Needs
. The Middle East, Mediterranean, and Africa (MEMA) region, encompassing 68 countries and 20% of the global population, contributes only 6% of the world's registered clinical trials. This editorial identifies eight key barriers to clinical research in the region: (1) limited collaboration with high-income country (HIC) universities supporting low-income country (LIC) research, (2) insufficient specialized training programs, (3) inadequate laboratory and technological infrastructure, (4) lack of research methodology integration in medical curricula, (5) underdeveloped local institutional review boards, (6) insufficient and unsustainable funding, (7) limited technology transfer from HICs to LICs, and (8) migration of skilled professionals to HICs. These challenges hinder the region's research capacity and global contribution. Proposed solutions include fostering HIC-LMIC partnerships, enhancing training through scholarships and local research centers, improving infrastructure via international collaboration, and developing robust ethical review systems. By addressing these barriers, LMICs can increase their contribution to global clinical research, promoting equitable health outcomes.
- Open Access
- 9 November 2025
- Published by Tunisian Society of Medical Sciences in La Tunisie medicale
- Vol. 103 (9) , 1143
Tunisie Médicale 2009–2025: A Shift Toward Evidence-Based Medicine and the Empowerment of Young Scientists
. This issue of Tunisie Médicale has reserved a place for the topic of literature review methodology. In practice, seven systematic reviews without meta-meta-analysis and four systematic reviews with meta-analyses have been published. These systematic reviews, which used correct methodology, covered neonatology, cardiology, pulmonology, rheumatology, anesthesia and intensive care, and psychiatry. Here is a stimulus, created for the first time, intended to encourage our young people to become data producers.
- 9 November 2025
- Published by Tunisian Society of Medical Sciences in La Tunisie medicale
- Vol. 103 (9) , 1143
Open AccessTunisie Médicale 2009–2025: A Shift Toward Evidence-Based Medicine and the Empowerment of Young Scientists
. This issue of Tunisie Médicale has reserved a place for the topic of literature review methodology. In practice, seven systematic reviews without meta-meta-analysis and four systematic reviews with meta-analyses have been published. These systematic reviews, which used correct methodology, covered neonatology, cardiology, pulmonology, rheumatology, anesthesia and intensive care, and psychiatry. Here is a stimulus, created for the first time, intended to encourage our young people to become data producers.
- Open Access
- 1 August 2025
- Published by Tunisian Society of Medical Sciences in La Tunisie medicale
- Vol. 103 (8) , 947-948
The Global Cost of Silencing Science
- 1 August 2025
- Published by Tunisian Society of Medical Sciences in La Tunisie medicale
- Vol. 103 (8) , 947-948
Open AccessThe Global Cost of Silencing Science
- Open Access
- 1 May 2025
- Published by Tunisian Society of Medical Sciences in La Tunisie medicale
- Vol. 103 (5) , 550-552
Efficacy and Safety of Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i) in Cardiac Amyloidosis: A Systematic Review: Study protocol
Background: Sodium-glucose transport protein 2 inhibitors (SGLT2i) have revolutionized the management of heart failure and renal dysfunction. Cardiac amyloidosis, an underdiagnosed cause of heart failure, primarily results from light-chain (AL) or transthyretin (ATTR) deposition. Emerging evidence suggests that SGLT2i may improve cardiac and renal outcomes in these patients. However, data on their efficacy and safety in cardiac amyloidosis remain limited. This study aimed to conduct a systematic review to evaluate the efficacy and safety of SGLT2i in cardiac amyloidosis. Methods: This systematic review and meta-analysis followed PRISMA guidelines and was registered on PROSPERO (CRD42024584183). A comprehensive search was performed across PubMed, Embase, Google Scholar, ScienceDirect, and Cochrane Library databases, including studies involving adult patients with AL or ATTR cardiac amyloidosis. Outcomes analyzed included cardiovascular mortality, heart failure hospitalizations, New York Heart Association (NYHA) functional class, left ventricular ejection fraction (LVEF), NT-proBNP, renal parameters, and adverse events. Data were synthesized using a random-effects model to account for heterogeneity, with effect measures expressed as risk ratios (RR) or mean differences (MD) and 95% confidence intervals (CIs). Results: Preliminary findings indicate that SGLT2i use in cardiac amyloidosis is associated with significant improvements in LVEF, NT-pro BNP levels, and renal parameters such as eGFR and albuminuria progression. A reduction in heart failure hospitalizations and stabilization of NYHA functional class were also observed. Adverse events, including genitourinary infections and orthostatic hypotension, were reported but were consistent with known SGLT2i safety profiles. However, heterogeneity in study designs and small sample ..(abstract truncated at 250 words).
- 1 May 2025
- Published by Tunisian Society of Medical Sciences in La Tunisie medicale
- Vol. 103 (5) , 550-552
Open AccessEfficacy and Safety of Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i) in Cardiac Amyloidosis: A Systematic Review: Study protocol
Background: Sodium-glucose transport protein 2 inhibitors (SGLT2i) have revolutionized the management of heart failure and renal dysfunction. Cardiac amyloidosis, an underdiagnosed cause of heart failure, primarily results from light-chain (AL) or transthyretin (ATTR) deposition. Emerging evidence suggests that SGLT2i may improve cardiac and renal outcomes in these patients. However, data on their efficacy and safety in cardiac amyloidosis remain limited. This study aimed to conduct a systematic review to evaluate the efficacy and safety of SGLT2i in cardiac amyloidosis. Methods: This systematic review and meta-analysis followed PRISMA guidelines and was registered on PROSPERO (CRD42024584183). A comprehensive search was performed across PubMed, Embase, Google Scholar, ScienceDirect, and Cochrane Library databases, including studies involving adult patients with AL or ATTR cardiac amyloidosis. Outcomes analyzed included cardiovascular mortality, heart failure hospitalizations, New York Heart Association (NYHA) functional class, left ventricular ejection fraction (LVEF), NT-proBNP, renal parameters, and adverse events. Data were synthesized using a random-effects model to account for heterogeneity, with effect measures expressed as risk ratios (RR) or mean differences (MD) and 95% confidence intervals (CIs). Results: Preliminary findings indicate that SGLT2i use in cardiac amyloidosis is associated with significant improvements in LVEF, NT-pro BNP levels, and renal parameters such as eGFR and albuminuria progression. A reduction in heart failure hospitalizations and stabilization of NYHA functional class were also observed. Adverse events, including genitourinary infections and orthostatic hypotension, were reported but were consistent with known SGLT2i safety profiles. However, heterogeneity in study designs and small sample ..(abstract truncated at 250 words).
- Open Access
- 23 April 2025
- Published by Open Exploration Publishing in Exploration of Medicine
- Vol. 6, 1001311
Right ventricular echocardiographic parameters predict severe sleep apnea syndrome in patients with heart failure
Aim: The study aimed to determine which right ventricle echocardiography parameters were associated with severe sleep apnea syndrome in heart failure patients with sleep apnea syndrome. Methods: A cross-sectional monocentric study was conducted, including 85 patients with stable heart failure. All patients underwent home respiratory polygraphy and transthoracic echocardiography with evaluation of the right ventricular echocardiographic parameters and sleep apnea syndrome severity. Results: The average age of the population was 69 years. The median left ventricular ejection fraction was 38% (33; 52). Sleep apnea syndrome was diagnosed in 71 patients (83.5%), with obstructive sleep apnea in 50 patients (58.8%) and central sleep apnea in 21 patients (24.7%). Severe sleep apnea syndrome was observed in 31% (n = 22) of patients. In the univariate analysis, right ventricle Tei index with a cutoff value > 0.50 (OR = 3; 95% CI = 1.06–8.56; p = 0.035), right ventricle fractional area change < 40 (OR = 4; 95% CI = 1.38–11; p = 0.09) and right ventricle free wall longitudinal strain with a cut-off value > –17 (OR = 3.5; 95% CI = 1.15–9.41; p = 0.002) increased the risk of having severe sleep apnea syndrome. In the multivariate analysis, the right ventricle free wall longitudinal strain was the only independent predictor for severe sleep apnea syndrome [hazard ratio (HR) = 0.892; 95% CI = 0.816–0.979; p = 0.036]. Conclusions: Right ventricle free wall longitudinal strain seems to be a strong predictor of severe sleep apnea syndrome in patients with stable chronic heart failure and sleep apnea syndrome.
- 23 April 2025
- Published by Open Exploration Publishing in Exploration of Medicine
- Vol. 6, 1001311
Open AccessRight ventricular echocardiographic parameters predict severe sleep apnea syndrome in patients with heart failure
Aim: The study aimed to determine which right ventricle echocardiography parameters were associated with severe sleep apnea syndrome in heart failure patients with sleep apnea syndrome. Methods: A cross-sectional monocentric study was conducted, including 85 patients with stable heart failure. All patients underwent home respiratory polygraphy and transthoracic echocardiography with evaluation of the right ventricular echocardiographic parameters and sleep apnea syndrome severity. Results: The average age of the population was 69 years. The median left ventricular ejection fraction was 38% (33; 52). Sleep apnea syndrome was diagnosed in 71 patients (83.5%), with obstructive sleep apnea in 50 patients (58.8%) and central sleep apnea in 21 patients (24.7%). Severe sleep apnea syndrome was observed in 31% (n = 22) of patients. In the univariate analysis, right ventricle Tei index with a cutoff value > 0.50 (OR = 3; 95% CI = 1.06–8.56; p = 0.035), right ventricle fractional area change < 40 (OR = 4; 95% CI = 1.38–11; p = 0.09) and right ventricle free wall longitudinal strain with a cut-off value > –17 (OR = 3.5; 95% CI = 1.15–9.41; p = 0.002) increased the risk of having severe sleep apnea syndrome. In the multivariate analysis, the right ventricle free wall longitudinal strain was the only independent predictor for severe sleep apnea syndrome [hazard ratio (HR) = 0.892; 95% CI = 0.816–0.979; p = 0.036]. Conclusions: Right ventricle free wall longitudinal strain seems to be a strong predictor of severe sleep apnea syndrome in patients with stable chronic heart failure and sleep apnea syndrome.
- Open Access
- 2 January 2025
- Published by Tunisian Society of Medical Sciences in La Tunisie medicale
- Vol. 103 (1)
Revues Prédatrices : Que pouvons-nous faire pour protéger leurs proies ?
- 2 January 2025
- Published by Tunisian Society of Medical Sciences in La Tunisie medicale
- Vol. 103 (1)
Open AccessRevues Prédatrices : Que pouvons-nous faire pour protéger leurs proies ?
- Open Access
- 8 April 2024
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 13 (1) , e47525
National Tunisian Study of Cardiac Implantable Electronic Devices: Design and Protocol for a Nationwide Multicenter Prospective Observational Study
Background: In Tunisia, the number of cardiac implantable electronic devices (CIEDs) is increasing, owing to the increase in patient life expectancy and expanding indications. Despite their life-saving potential and a significant reduction in population morbidity and mortality, their increased numbers have been associated with the development of multiple early and late complications related to vascular access, pockets, leads, or patient characteristics. Objective: The study aims to identify the rate, type, and predictors of complications occurring within the first year after CIED implantation. It also aims to describe the demographic and epidemiological characteristics of a nationwide sample of patients with CIED in Tunisia. Additionally, the study will evaluate the extent to which Tunisian electrophysiologists follow international guidelines for cardiac pacing and sudden cardiac death prevention. Methods: The Tunisian National Study of Cardiac Implantable Electronic Devices (NATURE-CIED) is a national, multicenter, prospectively monitored study that includes consecutive patients who underwent primary CIED implantation, generator replacement, and upgrade procedure. Patients were enrolled between January 18, 2021, and February 18, 2022, at all Tunisian public and private CIED implantation centers that agreed to participate in the study. All enrolled patients entered a 1-year follow-up period, with 4 consecutive visits at 1, 3, 6, and 12 months after CIED implantation. The collected data are recorded electronically on the clinical suite platform (DACIMA Clinical Suite). Results: The study started on January 18, 2021, and concluded on February 18, 2023. In total, 27 cardiologists actively participated in data collection. Over this period, 1500 patients were enrolled in the study consecutively. The mean age of the patients was 70.1 (SD 15.2) years, with a sex ratio of 1:15. Nine hundred (60%) patients were from the public sector, while 600 (40%) patients were from the private sector. A total of 1298 (86.3%) patients received a conventional pacemaker and 75 (5%) patients received a biventricular pacemaker (CRT-P). Implantable cardioverter defibrillators were implanted in 127 (8.5%) patients. Of these patients, 45 (3%) underwent CRT-D implantation. Conclusions: This study will establish the most extensive contemporary longitudinal cohort of patients undergoing CIED implantation in Tunisia, presenting a significant opportunity for real-world clinical epidemiology. It will address a crucial gap in the management of patients during the perioperative phase and follow-up, enabling the identification of individuals at particularly high risk of complications for optimal care. Trial Registration: ClinicalTrials.gov NCT05361759; https://classic.clinicaltrials.gov/ct2/show/NCT05361759 International Registered Report Identifier (IRRID): RR1-10.2196/47525
- 8 April 2024
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 13 (1) , e47525
Open AccessNational Tunisian Study of Cardiac Implantable Electronic Devices: Design and Protocol for a Nationwide Multicenter Prospective Observational Study
Background: In Tunisia, the number of cardiac implantable electronic devices (CIEDs) is increasing, owing to the increase in patient life expectancy and expanding indications. Despite their life-saving potential and a significant reduction in population morbidity and mortality, their increased numbers have been associated with the development of multiple early and late complications related to vascular access, pockets, leads, or patient characteristics. Objective: The study aims to identify the rate, type, and predictors of complications occurring within the first year after CIED implantation. It also aims to describe the demographic and epidemiological characteristics of a nationwide sample of patients with CIED in Tunisia. Additionally, the study will evaluate the extent to which Tunisian electrophysiologists follow international guidelines for cardiac pacing and sudden cardiac death prevention. Methods: The Tunisian National Study of Cardiac Implantable Electronic Devices (NATURE-CIED) is a national, multicenter, prospectively monitored study that includes consecutive patients who underwent primary CIED implantation, generator replacement, and upgrade procedure. Patients were enrolled between January 18, 2021, and February 18, 2022, at all Tunisian public and private CIED implantation centers that agreed to participate in the study. All enrolled patients entered a 1-year follow-up period, with 4 consecutive visits at 1, 3, 6, and 12 months after CIED implantation. The collected data are recorded electronically on the clinical suite platform (DACIMA Clinical Suite). Results: The study started on January 18, 2021, and concluded on February 18, 2023. In total, 27 cardiologists actively participated in data collection. Over this period, 1500 patients were enrolled in the study consecutively. The mean age of the patients was 70.1 (SD 15.2) years, with a sex ratio of 1:15. Nine hundred (60%) patients were from the public sector, while 600 (40%) patients were from the private sector. A total of 1298 (86.3%) patients received a conventional pacemaker and 75 (5%) patients received a biventricular pacemaker (CRT-P). Implantable cardioverter defibrillators were implanted in 127 (8.5%) patients. Of these patients, 45 (3%) underwent CRT-D implantation. Conclusions: This study will establish the most extensive contemporary longitudinal cohort of patients undergoing CIED implantation in Tunisia, presenting a significant opportunity for real-world clinical epidemiology. It will address a crucial gap in the management of patients during the perioperative phase and follow-up, enabling the identification of individuals at particularly high risk of complications for optimal care. Trial Registration: ClinicalTrials.gov NCT05361759; https://classic.clinicaltrials.gov/ct2/show/NCT05361759 International Registered Report Identifier (IRRID): RR1-10.2196/47525